ArticleBMC public health2020
Presentation intervals and the impact of delay on breast cancer progression in a black African population.
Article in BMC public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Delays in seeking, reaching and access to quality cancer care in sub-Saharan Africa: a systematic review.BMJ open · 2023Pooled it
- Health system factors that influence diagnostic and treatment intervals in women with breast cancer in sub-Saharan Africa: a systematic review.BMC public health · 2021Pooled it
- Determinants of Delayed Presentation and Advanced-Stage Diagnosis of Breast Cancer in Africa: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2021Pooled it
- Assessing health beliefs and patient delay among breast cancer patients in West Sumatra, Indonesia.MethodsX · 2026Article
- Assessing Delay Patterns in Diagnosis and Care Among Breast Cancer Patients in Ethiopia.Cancer reports (Hoboken, N.J.) · 2026Article
- Patient journey and timeliness of care for patients with breast cancer in Africa: a scoping review.BMJ open · 2025Article
- Health-seeking behaviour of breast cancer patients receiving care at a tertiary institution in Ghana.Ecancermedicalscience · 2024Article
- Defining national research priorities for prostate cancer in Zambia: using the Delphi process for comprehensive cancer policy setting in sub-Saharan Africa.BMJ oncology · 2024Article
- Remote Symptom Monitoring to Enhance the Delivery of Palliative Cancer Care in Low-Resource Settings: Emerging Approaches from Africa.International journal of environmental research and public health · 2023Article
- A gist on an obscure neoplasm in Ghana: gastrointestinal stromal tumours.BMC research notes · 2023Article
- Clinicopathologic Profile and Psychosocial Experiences of Nigerian Breast Cancer Survivors.JCO global oncology · 2023Article
- Article
- Delay in the diagnosis and treatment of breast cancer in Vietnam.Cancer medicine · 2021Article
- Barriers to Cancer Care in Northern Tanzania: Patient and Health-System Predictors for Delayed Presentation.JCO global oncology · 2021Article
- Assessment of Breast Cancer Management in Sub-Saharan Africa.JCO global oncology · 2021Article
- Determinants of late detection and advanced-stage diagnosis of breast cancer in Nigeria.PloS one · 2021Article
- Pattern of Emergency Presentation of Patients with Breast Cancer at the University of Benin Teaching Hospital.Journal of the West African College of SurgeonsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundThe help-seeking interval and primary-care interval are points of delays in breast cancer presentation. To inform future intervention targeting early diagnosis of breast cancer, we described the contribution of each interval to the delay and the impact of delay on tumor progression.
methodWe conducted a multicentered survey from June 2017 to May 2018 hypothesizing that most patients visited the first healthcare provider within 60 days of tumor detection. Inferential statistics were by t-test, chi-square test, and Wilcoxon-Signed Rank test at p-value 0.05 or 95% confidence limits. Time-to-event was by survival method. Multivariate analysis was by logistic regression.
resultsRespondents were females between 24 and 95 years (n = 420). Most respondents visited FHP within 60 days of detecting symptoms (230 (60, 95% CI 53-63). Most had long primary-care (237 of 377 (64 95% CI 59-68) and detection-to-specialist (293 (73% (95% CI 68-77)) intervals. The primary care interval (median 106 days, IQR 13-337) was longer than the help-seeking interval (median 42 days, IQR 7-150) Wilcoxon signed-rank test p = 0.001. There was a strong correlation between the length of primary care interval and the detection-to-specialist interval (r = 0.9, 95% CI 0.88-0.92). Patronizing the hospital, receiving the correct advice, and having a big tumor (> 5 cm) were associated with short intervals. Tumors were detected early, but most became advanced before arriving at the specialist clinic. The difference in tumor size between detection and arriving at a specialist clinic was 5.0 ± 4.9 cm (95% CI 4.0-5.0). The hazard of progressing from early to locally advanced disease was least in the first 30 days (3%). The hazard was 31% in 90 days.
conclusionMost respondents presented early to the first healthcare provider, but most arrived late at a specialist clinic. The primary care interval was longer than the help-seeking interval. Most tumors were early at detection but locally advanced before arriving in a specialist clinic. Interventions aiming to shorten the primary care interval will have the most impact on time to breast cancer presentation for specialist oncology care in Nigeria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.